Integrating In Silico and In Vitro Tools for Optimized Antibody Development—Design of Therapeutic Anti-oxMIF Antibodies
Altogether, this study shows that a small number of well-selected mutations was sufficient to substantially improve the biophysicochemical properties of imalumab.
Authors
- F. Rueker (ORCID: https://orcid.org/0000-0001-7639-2686)
- Alejandro A. Puchol Tarazona (ORCID: https://orcid.org/0000-0002-7869-6277)
- Randolf J. Kerschbaumer (ORCID: https://orcid.org/0009-0000-9842-5952)
- Michael Thiele (ORCID: https://orcid.org/0000-0002-3003-9999)
- Irina Mirkina (ORCID: https://orcid.org/0009-0003-0384-978X)
- Alexander Schinagl (ORCID: https://orcid.org/0000-0002-6060-969X)
- Gregor Rossmueller (ORCID: https://orcid.org/0009-0005-7318-479X)
Institutions
- Institute of Molecular Biotechnology (AT)
- BOKU University (AT)
Publication Details
- Journal
- Antibodies
- Published
- 2024-12-20
- DOI
- https://doi.org/10.3390/antib13040104
- Primary Topic
- Macrophage Migration Inhibitory Factor
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Synchrotron Radiation Facility
- Österreichische Forschungsförderungsgesellschaft
- Universität für Bodenkultur Wien
- EQUIPMENT BOKU VIENNA INSTITUTE OF BIOTECHNOLOGY